Role of the P2Y(13) Receptor in the Differentiation of Bone Marrow Stromal Cells into Osteoblasts and Adipocytes by Biver, G. et al.
	



	

 ! ∀
	

	
				


 !∀!#!∃!∀	!%&

#∋∋∋∋(∋∋∋)(∗+)(),∗−!!.!%		!!
 
/0!1(2
3/! &)∋+∗−

	4)5&+∗−	
	
6		

 
2
7	
08	
	
3	%
/	792
897!∗+&+)−),():;.77∃+∋(:∋
		<

#+∋+∋∋)	0+,++
#
∃
	=	

				

Author contributions: G.B.: Conception and design, collection and assembly data, data analysis and interpretation, manuscript writing; N.W.: 
collection and assembly data; A.G.: data analysis and interpretation; I.O.: collection and assembly data, data analysis and interpretation; T.R.A. :
Data analysis and interpretation; J.-M.B.: Conception and design, data analysis and interpretation, manuscript writing, final approval manuscript ; 
B.R. : Conception and design, collection and assembly data, data analysis and interpretation, manuscript writing, final approval manuscript 
Corresponding author: Dr. Bernard Robaye, 10 Rue A.Bolland, Université Libre de, Bruxelles, Gosselies 6041, Belgium. E-mail address: 
brobaye@ulb.ac.be. Tel: +3226509839; Abbreviations : ADP?S : adenosine-5’-O-(2-thiodiphosphate); ALP : alkaline phosphatase; BMSC : bone 
marrow stromal cells; CFU : colony forming unit; CFU-ALP : alkaline phosphatase-positive colony forming unit; CFU-F : colony forming unit-
fibroblast; COLI : collagen of type I;, HPRT : hypoxanthine-guanine phosphoribosyltransferase; MSC: mesenchymal stem cells; ns. : not significant; 
OSX: osterix; WT : wild-type. NS : non stimulated; DGAA: dexamethasone/ ?-glycerophosphate/ ascorbic acid; DII : dexamethasone/insuline/3-
isobutyl-methylxanthine.; Received October 02, 2012; accepted for publication March 26, 2013; 1066-5099/2013/$30.00/0 doi: 10.1002/stem.1411 
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and 
proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi:
10.1002/stem.1411 
STEM CELLS
®
TISSUE-SPECIFIC STEM CELLS
Role of the P2Y13 receptor in the differentiation of bone marrow 
stromal cells into osteoblasts and adipocytes 
Galadrielle Biver1, Ning Wang3, Alison Gartland3, Isabel Orriss4, Timothy R. Arnett4, Jean-Marie 
Boeynaems2, Bernard Robaye1
1)Institute of Interdisciplinary Research, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, 
Université Libre de Bruxelles, 6041 Gosselies, Belgium; 2)Institute of Interdisciplinary Research, Institut de Recherche 
Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles and Department of Medical 
Chemistry, Erasme Hospital, 1070 Brussels, Belgium; 3)The Mellanby Centre for Bone Research Department of 
Human Metabolism, The University of Sheffield, Sheffield S10 2RX, United Kingdom; 4) Department of Cell and 
Developmental Biology, University College London, London WC1E 6BT, United Kingdom
Key words. P2Y13 receptor ? knock-out mice ? mesenchymal stem cell ? osteoblast ? adipocyte ? differentiation
ABSTRACT
Accumulating evidence indicates that extracellular 
nucleotides, signaling through purinergic receptors, 
play a significant role in bone remodeling. 
Mesenchymal stem cells (MSC) express functional 
P2Y receptors whose expression level is regulated 
during osteoblast or adipocyte differentiation. P2Y13-
deficient mice were previously shown to exhibit a 
decreased bone turnover associated with a reduction 
in the number of both osteoblasts and osteoclasts on 
the bone surfaces. We therefore examined whether 
P2Y13R activation was involved in the osteogenic 
differentiation of MSC. Our study demonstrated that 
ADP stimulation of P2Y13R
+/+ (but not P2Y13R
-/-)
adherent bone marrow stromal cells (BMSC) 
increased significantly the formation of alkaline 
phosphatase-colony forming units (CFU-ALP), as 
well as the expression of osteoblastic markers 
(Osterix, Alkaline Phosphatase, Collagen I) involved 
in the maturation of pre-osteoblasts into osteoblasts. 
The number of CFU-ALP obtained from P2Y13R
-/-
BMSC and the level of osteoblastic gene expression 
after osteogenic stimulation were strongly reduced 
compared to those obtained in wild-type cell cultures. 
In contrast, when P2Y13R
-/-
 BMSC were incubated in 
an adipogenic medium, the number of adipocytes 
generated and the level of adipogenic gene expression 
(PPAR?2 and Adipsin) were higher than those 
obtained in P2Y13R
+/+ MSC. Interestingly we 
observed a significant increase of the number of bone 
marrow adipocytes in tibia of P2Y13R
-/-
 mice. In 
conclusion, our findings indicate that the P2Y13R
plays an important role in the balance of osteoblast 
and adipocyte terminal differentiation of bone 
marrow progenitors. Therefore, the P2Y13 receptor 
can be considered as a new pharmacological target 
for the treatment of bone diseases like osteoporosis.
INTRODUCTION Bone marrow is a heterogeneous tissue 
composed of differentiated cells, lineage 
restricted progenitors and stem cells. Among 
P2Y13 receptor and BMSCs differentiation 
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these are the multipotent mesenchymal stem 
cells (MSCs) that are able to differentiate into a 
number of distinct cell lineages including 
osteoblasts, adipocytes, chondrocytes and 
myocytes [1, 2]. Osteoblasts and marrow 
adipocytes share a common mesenchymal 
precursor and their ability to differentiate along 
one of these two lineages is determined by 
growth factors, cytokines and various signaling 
molecules. Factors promoting osteoblast 
differentiation are generally considered as 
inhibitory for adipocyte maturation and vice 
versa [3-9]. In age–related osteoporosis or 
osteopenia, the decreased bone volume is at 
least partly due to the fact that bone marrow 
stromal cells have a reduced capacity to 
differentiate into osteoblasts but an increased 
capacity for adipocyte differentiation. This 
shift favouring the adipocyte over osteoblast 
lineage leads to progressive accumulation of 
fat cells in bones [4, 10]. Therefore the 
correction of such disrupted balance is a 
potential therapeutic target for osteoporosis 
treatment. Over the last decade, a new strategy 
involving MSCs transplantation has been 
developed to cure bone formation deficiency. 
Because osteoblasts and adipocytes share a 
common precursor among MSC population, 
the main issue of this strategy is to avoid the 
differentiation of these MSCs into adipocyte 
cell lineage. Therefore many studies focused 
on indentifying factors promoting osteogenesis 
and inhibiting adipogenesis in order to direct 
the differentiation toward osteogenic 
differentiation in vitro before transplantation 
[11-13]
The differentiation into both osteoblasts and 
adipocytes is typically described as a two step 
process: determination and maturation. Firstly, 
MSC differentiate into pre-osteoblasts or pre-
adipocytes and this requires the expression of 
the early transcription factors Runx2 in pre-
osteoblasts [14-16] and CEBP/? ?and PPAR?1
in pre-adipocytes [3, 17]. An essential feature 
of these pre-differentiated progenitors is that 
they exhibit a plasticity which allows a process 
of trans-differentiation into the other 
(reciprocal) lineage [18, 19]. 
Up-regulation of Runx2 expression is not 
sufficient for triggering osteoblast 
differentiation. Its transcription factor activity 
is regulated through the MAP kinases signaling 
pathway in cooperation with the small G 
protein Rho [14, 16, 20, 21]. Conversely, 
agents elevating intracellular cyclic AMP 
upregulate the expression and activity of the 
transcription factor, PPAR? [17, 22]. In mouse 
as well as in human, this nuclear receptor is 
present in two isoforms, PPAR?1 and PPAR?2, 
generated by alternative splicing. It is well 
established that they are both involved in the 
differentiation of MSCs into adipocytes, but 
several studies support that PPAR?2 is 
expressed later and more selectively in fat cell 
lineage. Moreover, PPAR?2 is known to have a 
greater specificity to induce adipogenesis [23-
25].
Growing evidence suggests that extracellular 
nucleotides play important roles in the 
regulation of bone metabolism [26-32]. 
Nucleotides are mainly intracellular but can be 
released through various mechanisms (i.e. cell 
lysis, exocytosis, membrane channels)[33]. In 
the extracellular environment, they activate 
ionotropic P2X (PX1-7) and metabotropic G-
protein coupled P2Y receptors (P2Y1, 2, 4, 6, 11, 12, 
13, 14) [34]. The P2Y13R is activated by ADP 
and is coupled to G?i and inter alia adenylyl 
cyclase inhibition. Expression of P2Y13R
mRNA has been detected in brain, liver, spleen 
and bone marrow [35-37]. Several P2Y 
receptor subtypes are activated by ADP (P2Y1,
P2Y12 and P2Y13). Since the availability of 
specific agonists and antagonists for these 
receptors is limited, the P2Y-deficient mice 
strains constitute a powerful tool for the 
identification of their physiological roles. 
Knockout mice have been generated for the 
P2Y1, 2,6 and 13 receptors and each strain 
displays a unique bone phenotype [38-41]. In 
particular, P2Y13-deficient (P2Y13R
-/-) mice 
exhibit a decreased bone turnover associated 
with a reduction in the number of both 
osteoblasts and osteoclasts [40]. We have used 
P2Y13R
-/- mice to investigate the functional 
expression of the P2Y13R in bone marrow 
stromal cells and its role in the differentiation 
of these cells into osteoblasts versus
adipocytes. This study provides evidence that 
the P2Y13R physiologically stimulates the 
P2Y13 receptor and BMSCs differentiation 
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differentiation of osteoblasts and inhibits that 
of adipocytes. 
MATERIALS AND METHODS
Animals 
P2Y13R
?/? mice that we previously generated 
were crossed with C57BL/6 mice for up to 10 
generations on a C57BL/6 genetic background 
[35]. All of the mice used in this study were 
generated using heterozygous parents and 
housed in a conventional animal facility. All of 
the animal studies were authorized by the 
Animal Care Use and Review Committee of 
the Université Libre de Bruxelles (CEBEA-
IBMM protocol 44). 
Preparation and culture of mouse bone 
marrow cells 
Mice were killed by cervical dislocation. 
Mouse BMSCs were obtained from femur and 
tibia of 8 month old female P2Y13 wild type 
and knockout C57BL/6 mice. The two femurs 
and tibias were collected and bone marrow 
cavities were flushed with PBS or bones were 
centrifuged as previously described [42]. Cells 
were cultured in ?MEM medium (Invitrogen, 
Carlsbad, NM) supplemented with 10% FBS, 
penicillin (50 units/ml) and streptomycin (50 
µg/ml) at 37°C in a humidified atmosphere 
containing 5% CO2. Non adherent cells were 
removed after 24 h and 5 days by washing with 
PBS. 
Flow cytometry analysis of cell surface 
markers
Cells collected by trypsin treatment (2.5mM in 
PBS/EDTA, 10 min, 37°C) were washed in 
FACS medium (0.5% BSA/0, 1% NaN3 (w/v) 
in PBS). 106 cells were incubated with 
antibody (2 µg/ml) in 100µl of FACS medium. 
After washing, the cell labeling was analysed 
using a Cytomics FC500 cytometer (Beckman 
Coulter). For each antibody, gating was 
determined based on appropriately stained 
controls. Anti-CD45, -Sca1, -PDGFR????CD90
and -CD44 antibodies were purchased from 
eBiosciences. 
Osteogenic and adipogenic differentiation 
For osteogenic differentiation, cells were 
cultured with osteogenic differentiation media 
(10nM dexamethasone; 50µg/ml ascorbic acid; 
5mM ?-glycerophosphate (Sigma-Aldrich, St. 
Louis, MO)) for 7 days after the primary 
culture. For adipogenic differentiation, cells 
were cultured in the adipogenic differentiation 
media (0.5mM IBMX; 10µg/ml insulin; 10nM 
dexamethasone (Sigma-Aldrich, St. Louis, 
MO)) for 14 days after the primary culture. 
The media were replaced every 3 or 4 days. 
Alkaline phosphatase (ALP) staining and 
measurement of CFU-ALP and CFU-F 
colonies 
Osteoblasts were detected using Naphthol Fast 
Red (Sigma-Aldrich, St. Louis, MO) staining 
as described previously [43]. After 7 days in 
osteogenic differentiation media, cells were 
washed with PBS and incubated for 20 minutes 
in Naphthol AS-MX/Fast Red solution 
(0.5mg/ml Naphthol;1mg/ml Fast Red in Tris 
0,1 M pH 7.2) in order to detect the ALP-
positive colonies (CFU-ALP). Cells were then 
counterstained with Mayer’s hematoxyline in 
order to detect the total colonies formed (CFU-
F). CFU were detected using binocular 
microscope. 
Alizarin red staining 
Alizarin red staining was performed after 14 
days culture in osteogenic medium. Cells were 
washed with PBS and fixed with 4% 
formaldehyde for 30 minutes at room 
temperature. The cell layers were washed with 
deionized water and allowed to air dry. The 
fixed cells were stained with 2% Alizarin red S 
pH 4.2 in deionized water (Sigma-Aldrich, St. 
Louis, MO). After 20 minutes cells were 
washed with deionized water and observed 
under light microscope in order to detect 
mineralized matrix nodules. 
Isolation of RNA, reverse transcription and 
quantitative PCR 
Total RNA was extracted using TriPure 
reagent (Roche, Basel, Switzerland) and 
quantified on a NanoDrop 1000 (Thermo 
Fisher Scientific, Waltham, MA). After DNase 
I treatment (Fermentas, Hanover, Germany), 
P2Y13 receptor and BMSCs differentiation 
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RNA was reverse-transcribed using the 
RevertAid H Minus M-MuLV reverse 
transcriptase kit following manufacture 
instructions (Fermentas). PCR was performed 
using the QiagenTaq Core Kit (Quiagen, 
Venlo, Netherlands). Quantitative RT-PCR 
was performed with the quantitative RT-PCR 
(qPCR) MasterMix for SYBR Green I (Biorad) 
on CXF86 Real time system. For qPCR, 
housekeeping genes were HPRT, RPL32 and 
RPL12. Primers were purchased from 
EUROGENTEC and their sequences are 
shown in Table I. 
Oil red O staining 
Lipid droplets accumulation 
was assessed by an Oil red O staining. After 14 
days in adipogenic medim, culture dishes were 
washed in PBS and cells were fixed in 4% 
formaldehyde for 1 hour. Cells were then 
washed with deionized water followed by 60 % 
isopropanol. The cells were stained with 0.6% 
Oil Red O solution in isopropanol. After four 
washes with deionized water, Oil Red O dye 
was eluted with 100% isopropanol and 
quantified by measuring the optical absorbance 
at 490 nm. 
Nile Red staining 
Adipocytes were detected using Nile Red 
staining (Sigma-Aldrich, St. Louis, MO) as 
described previously [6]. Briefly, after 14 days 
in adipogenic differentiation media, cells were 
washed in PBS and fixed in 4% formaldehyde 
for 30 min. The cells were stained with 1µg/ml 
Nile Red for 20 min at 4°C. Nile Red staining 
was detected using an inverted fluorescence 
microscope Zeiss Axio Observer Z1 with 
excitation at 485 nm and emission at 572 nm. 
The percentage of differentiated adipocytes 
was determined by counting cells stained by 
the lipid-specific dye Nile Red and normalizing 
them to the total cell number determined via 
nuclear 4,6-diamidino-2 phenylindole (DAPI) 
staining. An average value was determined by 
counting cells in at least 8 microscopic fields 
(50-70 cells/field). 
ATP and ADP assay 
Five days after primary culture, cells were 
incubated in HBSS supplemented or not with 
differentiation medium for 15 minutes. The 
amount of ATP or ADP in cell cultures 
supernatants was determined using the ATP 
bioluminescence assay kit or the ADP 
colorimetric/fluorometric assay kit (Sigma-
Aldrich, St. Louis, MO). Data are expressed as 
nmoles of ATP or ADP produced per mg of 
cell protein (determined by Lowry assay). The 
pannexin-1 mimetic blocking peptide 
10panx1 (WRQAAFVDSY) was supplied by 
R&D Systems. 
Histological analysis 
Female WT and P2Y13R
-/- mice were 
euthanized at age of 20 weeks. Left tibiae of 
mice were dissected free of soft tissue, fixed in 
10% buffered formalin, and embedded in 
paraffin wax. Three µm sections were cut using 
a Leica Microsystems Microtome and followed 
by Haematoxylin& Eosin (H&E) staining [44]. 
The number of adipocytes (N.Adi) was 
counted in a 0.75 mm2field, starting 0.25mm 
from the growth plate and viewed on a DMRB 
microscope (Leica Microsystems), and 
normalized to the bone marrow area (Ma.Ar) 
measured. 
Dual energy x-ray absorptiometry (DEXA) 
analysis of P2Y13R knockout mice 
Percentage fat content of P2Y13R knockout 
mice and corresponding wild type animals was 
measured by DEXA using a small animal 
scanner (Lunar PIXImus, GE Healthcare, 
Chalfont St Giles, UK). Data were analysed 
using the manufacturer’s software (version 
1.8).
Statistical analysis 
Non-parametric Mann Whitney tests were 
performed using Prism, version 5.00, for 
Windows (Graph Pad, San Diego, CA). 
RESULTS
ADP?S stimulates MSC differentiation into 
osteoblasts through the P2Y13R
To study the role of the P2Y13R in osteoblast 
differentiation, we used the classical model of 
adherent bone marrow cells as a source of stem 
cells [2]. We first observed that the P2Y13R
mRNA is present in bone marrow cells as well 
as in 5 days cultured adherent cells (Fig 1A). In 
order to determine if ADP through P2Y13R
P2Y13 receptor and BMSCs differentiation 
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activation could affect differentiation of MSC 
cells into osteoblasts, we stimulated both wild 
type (WT) and P2Y13R
-/- bone marrow adherent 
cells with ADP?S (a relatively stable analogue 
of ADP) for 7 days and identified the presence 
of CFU-ALP. As shown in Fig 1B, we 
observed that after ADP?S treatment the 
number of WT CFU-ALP was more than 
doubled compared to untreated control 
condition. This ADP?S-induced increase of 
CFU-ALP was absent in P2Y13R
-/- cultures. By 
quantitative RT-PCR, we observed that 
ADP?S stimulated osterix (OSX), ALP and 
collagen type I (COLI) mRNA expression in 
WT-derived cells; this effect was significantly 
reduced in P2Y13R
-/- cell cultures (Fig 1C). In 
contrast, ADP?S had no effect on Runx2 
mRNA expression. The Rho signaling pathway 
has been shown to be important in the process 
of MSC differentiation toward the osteoblastic 
lineage [21, 45]. As P2Y13R have been shown 
to activate this pathway [46], we tested the 
effect of the Rho inhibitor Y27632. In the 
presence of this Rho inhibitor, the stimulatory 
action of ADP?S on the expression of OSX, 
ALP and COLI mRNA was reduced by 49 %, 
35% and 36% respectively (Fig 1D). These 
data suggest that the activation of the P2Y13R
supports the differentiation of MSCs into 
osteoblasts in a Rho-dependent way and that 
this action occurs downstream of Runx2 
upregulation. 
P2Y13R gene deletion inhibits osteoblastic 
differentiation in an osteogenic medium 
To determine whether these effects of P2Y13R
activation have a physiological relevance, we 
compared the generation of CFU-ALP induced 
by an osteogenic medium containing 
dexamethasone-?glycerophosphate-ascorbic 
acid (DGAA) in P2Y13R
-/- and WT MSCs 
cultured in vitro. We first observed that 
P2Y13R mRNA expression was stable during 
osteoblast differentiation (Fig 2A). As 
expected, the average number of CFU-ALP 
detected was higher when WT cells were 
treated with osteogenic inducers (mean of 9.5 
CFU-ALP per dish) than with ADP?S
treatment (mean of 1.8 CFU-ALP per dish) 
(Fig 1A and 2B). The number of CFU-ALP 
formed in culture dishes of P2Y13R
-/- bone 
marrow cells was significantly lower than that 
counted in WT cultures. To confirm that the 
targeting of the P2Y13 gene affected the 
differentiation of MSCs into osteoblasts, we 
studied another specific characteristic of these 
bone forming cells i.e. the formation of 
mineralized matrix nodules. As expected, the 
number of Alizarin red-S stained nodules 
formed in culture dishes of P2Y13R
-/- culture 
dishes was also significantly lower than that 
counted in WT cultures (Fig 2C). Furthermore 
the DGAA-induced upregulation of OSX, ALP 
and COLI mRNA was reduced in cell cultures 
from P2Y13R
-/- mice, whilst Runx2 expression 
was unchanged (Fig 2D). 
This altered differentiation of MSCs toward the 
osteoblastic lineage could be due to an 
alteration in the differentiation capability of 
progenitor cells or to a decreased number of 
these progenitors. Both mechanisms seem to be 
involved since we observed that the total 
number of CFU (detected by a hematoxylin 
coloration) counted in P2Y13R
-/- cultures was 
reduced by 44%, and the percentage of CFU-
ALP among total CFU was also diminished by 
54% in cultures of P2Y13R
-/- MSCs (Fig 2E). 
Among bone marrow cells, MSCs are very rare 
(45). The experimental protocol we followed 
allows isolating them by adherence. However 
the population we got remained heterogeneous 
as shown by flow cytometry. On a FFC/SSC 
dot plot (data not shown) we identified a low 
size/low granularity population (population A) 
and a medium size/medium granularity one 
(population B); the former is mainly CD45-
(95%) while the latter is for the most part (75% 
of cells) CD45+. These haematopoietic cells are 
predominantly of the myeloid lineage as they 
were mainly CD11b+ (data not shown). To 
identify MSCs, we studied the expression of 
Sca-1 (stem cell antigen1), CD90, CD44 and 
PDGFR??(Platelet-derived growth factor 
receptor ?? among CD45- cells (46). As 
expected, we detected Sca-1+/CD90+, Sca-
1+/CD44+ and Sca-1+/ PDGFR?+ cells but in a 
very low proportion (Table II). Among CD45-
/Sca-1+ cells of both A and B subpopulations, 
we could not observe significant differences 
between WT and P2Y13R
-/- cell cultures in 
terms of CD90 or CD44 expression. 
Interestingly, among Sca-1+ cells, we detected 
P2Y13 receptor and BMSCs differentiation 
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a significantly reduced proportion of PDGFR?+
cells in P2Y13R
-/- cell cultures in the A 
population compared to WT cells. 
ATP release and metabolism 
These data suggested that maximal osteoblast 
differentiation requires P2Y13R activation and 
implied that ADP may be released in the 
extracellular space constitutively or in a 
regulated way. Therefore, we measured the 
concentration of ATP, the precursor of ADP, in 
the culture medium and observed that it was 
increased following addition of the osteogenic 
inducers and that this stimulatory effect was 
affected by a 10Panx inhibitor of Pannexin 
channel (Fig 3A). Interestingly, we also 
noticed that the DGAA treatment induced 
upregulation of NTPDase2 (also known as 
CD39L1) mRNA (Fig 3B). This 
ectonucleotidase preferentially hydrolyzes 
ATP into ADP, thereby leading to the 
accumulation of extracellular ADP [47]. 
Indeed, osteogenic inducers stimulated the 
accumulation of ADP in the culture 
supernatant (Fig 3C). 
P2Y13 gene targeting increases adipogenic 
differentiation 
As mentioned above, the osteoblast and 
adipocyte differentiations are linked and 
mutually exclusive. Therefore we wanted to 
ascertain the effect of P2Y13R gene deletion on 
adipocyte differentiation of bone marrow 
adherent cells. The expression of the P2Y13
messenger was stable during adipocyte 
differentiation induced by the dexamethasone-
insulin-IBMX (DII) cocktail (Fig 4A). Culture 
of P2Y13R
+/+ MSCs in a medium containing 
the adipogenic inducers induced the 
accumulation of cells with lipid droplets that 
can be evaluated by Oil Red O and Nile Red 
staining. As shown in Fig 4B, the amount of 
Oil Red O dye eluted from P2Y13R
-/- treated 
cells was higher than that eluted from WT 
treated cells. Moreover, the number of Nile 
Red positive cells was significantly increased 
in P2Y13R
-/- MSC cultures (Fig 4C) while we 
did not find any difference in cell or droplet 
sizes (data not shown). Furthermore the 
percentage of MSCs that spontaneously 
differentiated into adipocytes was significantly 
increased in P2Y13R
-/- cell cultures (Fig 4 D). 
These data show that the deletion of the 
P2Y13R favors the formation of new adipocytes 
from precursor cells but do not affect the fat 
cell size. 
While the mRNA expressions of CEBP/? ?and
PPAR?1 were not modified in P2Y13R-/- cells, 
that of PPAR?2 was increased at an early time 
(Fig 4E). Indeed, in WT cultures the 
stimulation of PPAR?2 mRNA expression was 
detectable after 7 days of DII treatment, but in 
P2Y13R
-/- cultures it was already observed at 
day 3. Moreover, the expression of adipsin (a 
marker of adipocyte differentiation [10, 48]) 
was higher in P2Y13R
-/- cells compared to WT 
cells (Fig 4E). It is interesting to notice that 
adipogenic differentiation stimulates 
accumulation of ATP and ADP (Fig 4F,G). 
These data suggest that the deletion of the 
P2Y13R favors the differentiation of MSCs into 
adipocytes by accelerating the expression of 
PPAR?2. 
P2Y13R deletion increases the accumulation 
of adipocytes in vivo 
To see if the increased capability of P2Y13R
-/- 
MSCs to differentiate into adipocytes observed 
in vitro translated to the in vivo situation, we 
performed histological analysis of the long 
bone cellular content. As illustrated in figure 5 
(A,B and C), the number of adipocytes in tibial 
sections of 20 week old female mice was more 
than doubled in P2Y13R
-/- mice compared to 
WT. There was however no difference in the 
percentage of total body fat measured by dual 
energy X-ray absorptiometry (DEXA) between 
WT and P2Y13R
-/- mice (Fig 5D). 
DISCUSSION
Growing evidence suggests a role for 
extracellular nucleotides and P2Y receptors in 
the differentiation of MSCs [26, 31, 49]. Zippel 
et al have recently shown that the mRNAs of 
each P2 receptor subtype are detectable in 
human MSC derived from adipose tissue or 
dental follicles. Moreover, the expression of 
P2Y1, P2Y2, P2Y4 and P2Y14 mRNAs is 
reduced after osteogenic differentiation while 
the expression of the P2Y4 and P2Y14 receptors 
is down-regulated after adipogenic 
P2Y13 receptor and BMSCs differentiation 
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differentiation and that of the P2Y11 receptor is 
up-regulated [49]. It was previously shown that 
P2Y13R
-/- mice exhibit a decreased bone 
turnover in vivo and that this phenotype is 
associated with a reduction in the number of 
osteoblasts at the surface of bone [40]. These 
data suggested that the P2Y13 receptor might 
be involved in the control of osteoblast and 
adipocyte differentiation from stem cells. 
Therefore, we have investigated the role of the 
P2Y13R in the generation of osteoblasts from 
adherent MSCs isolated from bone marrow. 
We show that ADP triggers the generation of 
CFU-ALP and stimulates the expression of 
ALP, OSX and COLI mRNA, three osteoblast 
markers. These effects involve the activation of 
the P2Y13R since the stimulatory effect of ADP 
is reduced in P2Y13R
-/- MSCs cell culture. To 
determine at which level of the differentiation 
process the stimulation of the P2Y13R favors 
the osteoblastic lineage, we tested the mRNA 
expression of the Runx2 transcription factor, 
which is one of the earliest determinants of 
osteoblast differentiation driving the 
differentiation of MSCs into pre-osteoblasts 
[14]. Its pro-osteogenic activity implies not 
only the up-regulation of its expression but 
also post-translational modifications like 
phosphorylation, which depend on the Rho and 
MAP kinase signaling pathways [16, 20]. ADP 
does not modulate Runx2 expression in these 
cultures, but increases the mRNA level of 
OSX, another important transcription factor 
involved in osteoblast differentiation that is 
under the control of Runx2. ATP, the precursor 
of ADP, has been shown to stimulate Runx2 
DNA-binding activity in osteoblast-like 
HOBIT cell line in an Erk1, 2-dependent way 
[50]. Moreover, the RhoA/ROCK1 signaling 
pathway is linked to P2Y13R activation in 
murine osteoblasts isolated from calvaria and 
ADP stimulation of human hepatocytes leads 
to RhoA/ROCK1 activation [40, 46]. In 
agreement with these observations, we show 
here that an inhibitor of the Rho G protein (the 
compound Y27632) reduced ADP-induced up-
regulation of OSX, ALP and COLI mRNA 
expression in MSCs. Therefore, we suggest 
that ADP activates the differentiation of pre-
osteoblasts into osteoblasts by stimulating the 
DNA binding activity of Runx2 through 
RhoA/ROCK1 signaling pathways in a 
P2Y13R-dependent way. 
The capability of the P2Y13R to modulate the 
differentiation of MSCs into the osteoblastic 
lineage is relevant at the physiological level, as 
the number of the CFU-ALP and mineralized 
nodules induced by the osteogenic cocktail 
DGAA is largely reduced in P2Y13R
-/- cell 
cultures. This is due both to the reduction of 
total CFU obtained after culture of bone 
marrow stromal cells and to their decreased 
ability to differentiate into osteoblasts. The 
reduction of total CFU could be correlated to 
the decreased number of CD45-/Sca-
1+/PDGFR?+ seen in a sub-population of 
P2Y13R
-/- adherent cells. Indeed, it has been 
recently shown that CD45-/Sca-1+/PDGFR?+
cells isolated from the bone marrow have the 
highest capability to generate CFU-Fs after 
plating (46). Human MSCs isolated from the 
bone marrow or adipose tissue express the 
P2Y13R [26, 49]. However, because the cell 
population we stimulated in this work was 
heterogeneous, we cannot exclude that the 
effect of the P2Y13R on osteoblast 
differentiation is partly indirect involving other 
cells that stem cells. Among cells we obtained 
after 5 days of preculture, we identified 
CD45+/CD11b+ myeloid cells. In this context, 
it is interesting to refer to the work of Pirraco 
et al. showing that the co-culture of human 
macrophages with human bone marrow 
derived MSCs leads to increase differentiation 
into osteoblasts compared to monoculture of 
MSCs [51]. 
We confirm that the influence of the P2Y13R
on osteogenesis is downstream of the Runx2 
up-regulation, as its expression is not altered 
by the P2Y13R gene targeting. But the 
expression of osterix is significantly reduced in 
mutated MSCs. This suggests that the P2Y13R
does not control the initiation of MSCs 
differentiation, but the maturation of pre-
osteoblasts into osteoblasts. 
The fact that the differentiation of MSCs into 
osteoblasts requires P2Y13R expression implies 
that the osteogenic cocktail may favor 
accumulation of ADP in the extracellular 
space. This is supported by the observation that 
the incubation of MSCs with apyrase, that 
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hydrolyses extracellular nucleotides, inhibits 
osteoblast differentiation [49]. We observed 
that in osteogenic conditions the concentration 
of extracellular ATP, as well as of ADP, is 
enhanced compared to control conditions. In 
human bone marrow stromal cells, it has been 
shown that ecto-nucleotidases are expressed 
and that the supplementation of culture 
medium with ATP leads to transient production 
of ADP [31]. We also detected the expression 
of the ectonucleotidases NTPDase2 (CD39L1) 
which preferentially hydrolyses ATP into ADP 
[47].Therefore, we conclude that the DGAA-
induced maturation of pre-osteoblasts into 
osteoblasts involves partially the release of 
ATP and its conversion through CD39L1 into 
ADP that activates the P2Y13R. The release of 
nucleotides involves multiple mechanisms like 
cell lysis, secretory granules exocytosis, 
membrane transporter and hemi-channels like 
connexin and pannexin [33, 52]. DAAG-
induced ATP release seems to result from the 
opening of pannexin hemichannels as DGAA-
induced ATP accumulation is reduced by 
10Panx, an inhibitory peptide of Pannexin 1. 
The impaired ability of P2Y13R
-/- MSCs to 
differentiate into osteoblasts in vitro may 
explain the decreased number of osteoblasts 
present in P2Y13R
-/-bones in vivo, leading to 
reduced trabecular bone volume[40]. It is 
important to mention that the ADP effects that 
we observed were not completely abolished in 
P2Y13R
-/- cell cultures suggesting implication 
of the other purinergic receptors as P2Y1 or 
P2Y12 or adenosine receptors. Several studies 
support that the P2Y1 receptor promotes 
proliferation of undifferentiated cells and 
osteoblasts, but there are no indication to our 
knowledge regarding to a role of this receptor 
in MSCs differentiation [32, 53]. On the 
contrary, the expression of the P2Y1 mRNA is 
down-regulated during osteogenic 
differentiation of human adipose-tissue derived 
stem cells [49].Recently, it has been shown 
that the expression of the P2Y12 receptor 
mRNA is up-regulated in a model of rat 
osteoblast differentiation of precursors isolated 
from calvarial bones [54]. Finally, adenosine 
that can accumulate into extracellular space 
after ADP hydrolysis, is well known to 
promote osteoblast differentiation [55, 56]. 
The differentiation of MSCs into osteoblastic 
or adipogenic lineages are not independent 
processes: molecular components promoting 
one cell fate inhibit the mechanisms governing 
the differentiation of the alternative lineage [4, 
7]. This is also the case for the P2Y13R. Its 
expression is required for full osteoblastic 
differentiation as discussed above, while the 
P2Y13R gene targeting increases the potential 
of MSCs to generate adipocytes. Indeed, the 
number of adipocytes generated in P2Y13R
-/-
MSCs in response to the adipogenic cocktail 
and the expression of adipocyte markers like 
adipsin are enhanced compared to that obtained 
in WT culture. This suggests that the activation 
of the P2Y13R inhibits adipocyte differentiation 
and implies that the adipogenic stimulation 
stimulates the accumulation of ADP in the 
extacellular space, what we also observe. 
CEBP/? ?and PPAR?1 are transcription factors 
that regulate the first steps of adipocyte 
differentiation [23, 57]. The P2Y13R gene 
targeting does not modulate their mRNA 
expression. However, the earlier expression of 
PPAR?2 observed in P2Y13R-/- cultures 
correlates with increased adipocyte formation 
and adipsin expression, suggesting that the 
P2Y13R controls negatively the maturation of 
pre-adipocytes into adipocytes. It could be 
linked to the control of the transcriptional 
expression of PPAR?2 by cAMP-linked 
signaling pathway [22]. Indeed the P2Y13R
belongs to the G protein-coupled receptor 
superfamily and activates G?i/o proteins 
inhibiting cAMP production [37]. The gene 
deletion of G?i/o-coupled type 1 cannabinoid 
receptor CB1 leads to an analogous phenotype 
in terms of MSCs differentiation: reduced 
production of osteoblasts but increased 
generation of adipocytes [3]. Moreover, it has 
been recently described that an impairment of 
Rho signaling upregulates PPAR?2 expression 
as well as adipocyte formation [45, 58]. 
Therefore a cooperation between cAMP 
inhibition and Rho signaling pathways may be 
the effector mechanism downstream the 
P2Y13R stimulation to control negatively the 
differentiation of adipocytes. The fact that we 
observed a significant increase of adipocytes in 
non-induced P2Y13R
-/- MSCs culture as well as 
in the bone marrow of P2Y13R
-/- mice, but not 
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in the total body fat, underscores the relevance 
of our observations in relation with bone 
diseases. Osteoporosis, for example, is a 
disease in which resorption by osteoclasts is 
not sufficiently compensated by bone 
formation [59] and is associated with increased 
bone marrow adipogenesis[60, 61]. The 
identification of molecular components able to 
favor osteogenesis and reduce adipogenesis 
will help to design new drugs for bone diseases 
cure. 
CONCLUSION AND SUMMARY
In conclusion, this study demonstrates that the 
P2Y13R is a physiological determinant of 
MSCs differentiation. This receptor is one of 
the factors controlling the balance between 
osteogenesis and adipogenesis, at the level of 
the maturation of pre-committed progenitor 
cells. Our in vitro observations are consistent 
with our in vivo data showing a high marrow 
fat content in the bone of the P2Y13 knockout 
mice and the previously reported decreased 
bone formation in these mice [40]. Agonists of 
the P2Y13R might be used to favor osteoblast 
differentiation and bone formation, in 
particular in case of MSC transplantation. 
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Figure 1. Osteogenic differentiation of BMSCs: Effect of ADP?S
(A) Detection of P2Y13 messenger: RT-PCR (29 cycles) was performed using cDNA synthesized 
from RNAs extracted from freshly isolated BMSCs or cells cultured for 5 days in MEM.HPRT 
gene was used to control cDNA quality. 
(B) CFU-ALP formation: 5x106 marrow cells collected by flushing method were seeded on 6-wells 
plates and cultured for 5 days in MEM medium followed by 7 days in MEM medium supplemented 
or not with 50µM ADP?S (replaced every 2 days). To identify CFU-ALP, cells were stained with 
Naphthol-FastRed as described in the material and methods section. Data are expressed as mean 
±SD of 6 cell preparations; each point is the mean of 3 wells from each of these preparations. * 
p<0.05 
(C) Runx2, OSX, ALP and COL I expression: 7.5x106 cells collected by centrifugation were seeded 
on Petri dishes and cultured for 5 days in MEM medium followed by 1, 3 or 5 days in MEM 
supplemented or not with ADP?S (50µM). RNAs are extracted 1, 3 or 5 days after ADP?S
additions. Total RNAs were extracted as described in the material and methods section and mRNA 
expression was determined by RT-qPCR. Quantitative mRNA values were normalized by the 
amount of HPRT, RPL13 and RPL32, and results represent the ratio between ADP?S-stimulated 
and control cultures. Data are means ± SD of 6 cells preparations. Data were normalized to those of 
the housekeeping gene HPRT, RPL32 and RPL12. *p<0.05;**p<0.01 
(D) Effect of Rho inhibitor Y27632 : 7.5x106 cells collected by centrifugation were seeded on Petri 
dishes and were cultured for 5 days in MEM medium followed by 1 or 3 days in MEM 
supplemented with ADP?S (50µM) with or without Y7632 (10µM). RNA extraction and mRNA 
quantification were performed as described above. Data are means ± SD of 5 (OSX and RUNX2), 
6 (ALP) or 4 (COLI) cell preparations. Data were normalized to those of the housekeeping gene 
HPRT, RPL32 and RPL12. *p<0.05;**p<0.01 
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Figure 2. Osteogenic differentiation of BMSCs: comparison between P2Y13R
-/- and WT mice 
(A) P2Y13R expression: quantitative RT-PCR was performed using cDNA synthesized from RNAs 
extracted from cells cultured for 5 days in MEM and cells cultured additionally for 1, 3, 5 and 7 
days in MEM supplemented with 50?g/ml ascorbic acid, 5mM ?-glycerophosphate and 10nM 
dexamethasone. Data are means ± SD of 4 cells preparation. Data were normalized to those of the 
housekeeping gene HPRT, RPL32 and RPL12. 
(B) CFU-ALP formation: 5x106 marrow cells collected by flushing method were seeded on 6-wells 
plates and cultured for 5 days in MEM followed by 7 days in MEM supplemented with 50?g/ml 
ascorbic acid, 5mM ?-glycerophosphate and 10nM dexamethasone. Top panel: data are expressed 
as mean of CFU-ALP ± SD; nWT =14, n P2Y13R
-/- = 16, ***p<0.001. 
Bottom panel: picture of CFU-ALP in culture dishes. 
(C) Mineralized nodule formation : 5x106 marrow cells collected by flushing method were seeded 
on 6-wells plates and cultured for 5 days in MEM followed by 14 days in MEM supplemented with 
50?g/ml ascorbic acid, 5mM ?-glycerophosphate and 10nM dexamethasone. Top panel: data are 
expressed as mean ± SD; nWT =11, n P2Y13 R
-/- = 10, ***p<0.001. 
Bottom panel: picture of mineralized nodules in culture dishes. 
(D) RUNX2, OSX, ALP and COLI expression: quantative RT-PCR for RUNX2, OSX, ALP, OSX 
was performed as in figure 1C, but cells were treated for 5 days in MEM, followed by 1 
(RUNX2,OSX), 3( ALP) or 5 (COLI) days in MEM supplemented with 50?g/ml ascorbic acid, 
5mM ? glycerophosphate and 10nM dexamethasone. Data are means ± SD of 6 cell preparations. 
Data were normalized to those of the housekeeping gene HPRT, RPL32 and RPL12. 
*p<0.05;**p<0.01 
(E) CFU formation: BMSCs were seeded and treated as described in Figure 2A. Total CFU (left) 
were detected using hematoxylin staining and the percentage of CFU-ALP among total CFU (right) 
was quantified. Data are expressed as mean of CFU± SD, nWT =14, nP2Y13R
-/- = 16, ***p<0.001. 
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Figure 3. ATP release and metabolism 
(A) ATP release: cells were cultured for 5 days in MEM medium and 15 min in MEM 
supplemented with 50?g/ml ascorbic acid, 5mM ? glycerophosphate and 10nM dexamethasone in 
the presence or not of Pannexin 1 inhibitor ,10PANX ( 100µM). The concentration of ATP in the 
supernatant was determined by luminescence using an ATP assay kit and normalized to protein 
content as described in the material and methods section. Data are means ± SD of 4 cells 
preparation. *p<0.05 
(B) CD39L1 expression: quantative RT-PCR for CD39L1 was performed as in figure 2D. Data are 
means ± SD of 4 cells preparation. Data were normalized to those of the housekeeping genes 
HPRT, RPL32 and RPL12. *p<0.05 
(C) ADP release: cells were cultured for 5 days in MEM medium and 15 min in HBSS 
supplemented with 50?g/ml ascorbic acid, 5mM ? glycerophosphate and 10nM dexamethasone. 
The concentration of ADP in the supernatant was determined using the ADP Colorimetric/ 
Fluorometric Assay Kit and normalized to protein content as described in the material and methods 
section. Data are means ± SD of 5 cells preparation. *p<0.05 
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Figure 4. Adipogenic differentiation of BMSCs : comparison between P2Y13R
-/- and WT mice 
(A) P2Y13R expression: quantitative RT-PCR was performed using cDNA synthesized from RNAs 
extracted from cells cultured for 5 days in MEM and cells cultured additionally for 1, 3, 5 and 7 
days in MEM supplemented with 10nM dexamethasone, 0.5mM IBMX and 10?g/ml insulin. Data 
are means ± SD of 4 cell preparations. Data were normalized to those of the housekeeping gene 
HPRT, RPL32 and RPL12. 
(B) Lipid droplet accumulation : 2.5x106 marrow cells collected by the flushing method were 
seeded on 6-wells plates and cultured for 5 days in MEM medium followed by 14 days incubation 
in MEM medium supplemented with 10nM dexamethasone, 0.5mM IBMX and 10?g/ml insulin. 
The lipid droplets accumulation was assessed by Oil Red O assay as described in the materiel and 
method section. Data are means ± SD (nWT=12 and nKO=9). *p<0.05 
(C) Adipocyte formation: 5x105 marrow cells collected by the flushing method were seeded on 
Cellview™ dishes and cultured for 5 days in MEM medium followed by 14 days incubation in 
MEM medium supplemented with 10nM dexamethasone, 0.5mM IBMX and 10?g/ml insulin. The 
lipid droplets of adipocytes were identified by Nile Red staining as described in the material and 
methods section.
Left panel : quantification of Nile Red positive cells; data are expressed as mean ± SD, (nWT=6 
and nP2Y13R
-/-=6), **p<0.01. 
Right panel : fluorescence microphotographs taken at ×20 of Nile Red staining. 
(D) Adipocyte formation: 5x105 marrow cells collected by the flushing method were seeded on 
Cellview™ dishes and cultured for 21 days in MEM medium. The lipid droplets of adipocytes were 
identified by Nile Red staining as described in the material and methods section.
Data are expressed as mean ± SD, (nWT=5 and nP2Y13R
-/-=5) **p<0.01 
(E) CEBP/?? PPAR???? PPAR?2 ?and ?adipsin expression: 7.5x106 cells, collected by centrifugation, 
were seeded on Petri dishes and cultured for 5 days in MEM medium followed by 1 (CEBP?), 3 
(PPAR?1 and PPAR?2), 7 (PPAR?2) or 10 (ADIPSIN) days in MEM supplemented with 10 nM 
dexamethasone, 0.5mM IBMX and 10?g/ml insulin. Total RNA was extracted as described in the 
material and methods section and mRNA expression was determined by RT-qPCR. Quantitative 
mRNA values were normalized to the amount of HPRT, RPL13 and 32, and results are given as the 
ratio between adipogenic and control medium. Data are means ± SD of 6 cells preparation. Data 
were normalized to those of the housekeeping gene HPRT, RPL32 and RPL12. *p<0.05, **p<0.01 
(F) ATP release: cells were cultured for 5 days in MEM medium and 15 min in MEM 
supplemented with 10 nM dexamethasone, 0.5mM IBMX and 10?g/ml insulin. The concentration 
of ATP in the supernatant was determined by luminescence using ATP assay kit and normalized to 
protein content as described in the material and methods section. Data are means ± SD of 4 cell 
preparations. *p<0.05 
(G) ADP release: cells were cultured for 5 days in MEM medium and 15 minutes in HBSS 
supplemented with 10 nM dexamethasone, 0.5mM IBMX and 10?g/ml insulin. The concentration 
of ADP in the supernatant was determined by ADP Colorimetric/Fluorometric Assay Kit and 
normalized to protein content as described in the material and methods section. Data are means ± 
SD of 4 cell preparations. *p<0.05 
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Figure 5. Fat content in bone marrow and total body : comparison between WT and P2Y13R
-/- mice
(A) Transparent round adipocytes can be identified in the tibial proximal end bone marrow, scale 
bar = 0.5mm. 
(B) Adipocytes were marked as ‘a’ in magnified view of bone marrow area, scale bar = 50 ?m. 
(C) The number of adipocytes (N.Adi) normalized by area of bone marrow (Ma.Ar) was quantified 
for mice at 20 weeks of age, nWT=5, nP2Y13R
-/-=6. Data are mean ± SEM, ** p<0.01. 
(D) DEXA analysis of P2Y13R
-/- mice and their corresponding WT : results are expressed in % fat 
content (nWT=7 and nP2Y13R
-/-=10). 
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TABLE 1. List of specific primers used in this study 
 Gene Forward (5?–3?) Reverse (5?–3?)
qPCR P2Y13 CATATCCAGTGCCTGTGTGG TGTTGCATGTGCCTCTC
TTC 
 RUNX2 CCCAGCCACCTTTACCTACA TATGGAGTGCTGCTGGT
CTG
 ALP CCAGCAGGTTTCTCTCTTGG CTGGGAGTCTCATCCTG
AGC 
 COLI GAGCGGAGAGTACTGGATCG GCTTCTTTTCCTTGGGG
TTC  
 OSX ACTCATCCCTATGGCTCGTG  GGTAGGGAGCTGGGTT
AAGG  
 PPAR 
1
TTTTCAAGGGTGCCAGTTTC AATCCTTGGCCCTCTGA
GAT 
 PPAR 
2
CTTCGCTGATGCACTGCCTA CATCACGGAGAGGTCC
ACAG 
 ADIPSI
N
TGCACAGCTCCGTGTACTTC CACCTGCACAGAGTCGT
CAT
 CD39L
1
AACCAGTCCATCTGAAGATCC
AGATAAT 
AGTAGAAAGCAGAAAA
GGCTATGAAGTT 
 RPL12 ATGACATTGCCAAGGCTACC CAAGACCGGTGTCTCAT
CTGC
 RPL32 GGCACCAGTCAGACCGATAT CAGGATCTGGCCCTTGA
AC
 HPRT AAGCTTGCTGGTGAAAAGGA TTGCGCTCATCTTAGGC
TTT 
RT-PCR P2Y13 ATTCGTGGGTTGAGCTAGTAA ATCAGGGACCAGACGG
AAAT 
 HPRT CCTGCTGGATTACATTAAAGC
ACTG 
GTCAAGGGCATATCCA
ACAACAAAC 
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TABLE II: Immunophenotyping of adherent bone marrow cells 
Population A WT P2Y13R
-/-
CD45+ 4.76±1.72 4.00±2.66 ns 
CD45- 95.57±1.46 93.45±4.61 ns 
CD45-Sca-1+CD90+ 0.08±0.05 0.07±0.07 ns 
CD45-Sca-1+CD44+ 0.14±0.05 0.16±0.07 ns  
CD45-Sca-1+PDGFR?+ 0.18±0.05 0.10±0.05 p<0,05
Population B WT P2Y13R
-/-
CD45+ 74.8±7.8 82.16±10.43 ns 
CD45- 24.5±2.81 19.23±3.66 ns 
CD45-Sca-1+CD90+ 0.7±0.16 0.63±0.27 ns 
CD45-Sca-1+CD44+ 3.97±1.38 4.22±1.68 ns  
CD45-Sca-1+PDGFR?+ 3.07±2.41 1.77±1,11 ns 
